Comparison of susceptibility to ertapenem, imipenem, meropenem and ceftolozane/tazobactam between non-cHR and cHR isolates based on manual testing by BMD
| . | All (N = 173) . | Non-cHR (N = 118) . | cHR (N = 55) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | |
| Ertapenem | 0.25/0.50 | 93 | 4 | 3 | 0.125/0.50 | 95 | 4 | 1 | 0.25/1 | 89 | 5 | 5 |
| Imipenem | 0.25/0.50 | 100 | 0 | 0 | 0.25/0.50 | 100 | 0 | 0 | 0.25/0.50 | 100 | 0 | 0 |
| Meropenem | 0.0625/0.125 | 100 | 0 | 0 | 0.0625/0.125 | 100 | 0 | 0 | 0.0625/0.0625 | 100 | 0 | 0 |
| Ceftolozane/ tazobactam | 0.25/0.50 | 99 | 0 | 1 | 0.25–4/0.5–4 | 100 | 0 | 0 | 0.25–4/0.5–4 | 96 | 0 | 4 |
| . | All (N = 173) . | Non-cHR (N = 118) . | cHR (N = 55) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | |
| Ertapenem | 0.25/0.50 | 93 | 4 | 3 | 0.125/0.50 | 95 | 4 | 1 | 0.25/1 | 89 | 5 | 5 |
| Imipenem | 0.25/0.50 | 100 | 0 | 0 | 0.25/0.50 | 100 | 0 | 0 | 0.25/0.50 | 100 | 0 | 0 |
| Meropenem | 0.0625/0.125 | 100 | 0 | 0 | 0.0625/0.125 | 100 | 0 | 0 | 0.0625/0.0625 | 100 | 0 | 0 |
| Ceftolozane/ tazobactam | 0.25/0.50 | 99 | 0 | 1 | 0.25–4/0.5–4 | 100 | 0 | 0 | 0.25–4/0.5–4 | 96 | 0 | 4 |
S, susceptible; I, intermediate; R, resistant.
Comparison of susceptibility to ertapenem, imipenem, meropenem and ceftolozane/tazobactam between non-cHR and cHR isolates based on manual testing by BMD
| . | All (N = 173) . | Non-cHR (N = 118) . | cHR (N = 55) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | |
| Ertapenem | 0.25/0.50 | 93 | 4 | 3 | 0.125/0.50 | 95 | 4 | 1 | 0.25/1 | 89 | 5 | 5 |
| Imipenem | 0.25/0.50 | 100 | 0 | 0 | 0.25/0.50 | 100 | 0 | 0 | 0.25/0.50 | 100 | 0 | 0 |
| Meropenem | 0.0625/0.125 | 100 | 0 | 0 | 0.0625/0.125 | 100 | 0 | 0 | 0.0625/0.0625 | 100 | 0 | 0 |
| Ceftolozane/ tazobactam | 0.25/0.50 | 99 | 0 | 1 | 0.25–4/0.5–4 | 100 | 0 | 0 | 0.25–4/0.5–4 | 96 | 0 | 4 |
| . | All (N = 173) . | Non-cHR (N = 118) . | cHR (N = 55) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | MIC50 (mg/L)/ MIC90 (mg/L) . | S (%) . | I (%) . | R (%) . | |
| Ertapenem | 0.25/0.50 | 93 | 4 | 3 | 0.125/0.50 | 95 | 4 | 1 | 0.25/1 | 89 | 5 | 5 |
| Imipenem | 0.25/0.50 | 100 | 0 | 0 | 0.25/0.50 | 100 | 0 | 0 | 0.25/0.50 | 100 | 0 | 0 |
| Meropenem | 0.0625/0.125 | 100 | 0 | 0 | 0.0625/0.125 | 100 | 0 | 0 | 0.0625/0.0625 | 100 | 0 | 0 |
| Ceftolozane/ tazobactam | 0.25/0.50 | 99 | 0 | 1 | 0.25–4/0.5–4 | 100 | 0 | 0 | 0.25–4/0.5–4 | 96 | 0 | 4 |
S, susceptible; I, intermediate; R, resistant.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
